peppersite
Peptide

PT-141

PT-141, also called bremelanotide, is a lab-made ring-shaped peptide that switches on two melanocortin receptors in the brain, MC3R and MC4R. It is the active ingredient in Vyleesi, approved for premenopausal women with a specific form of low sexual desire.

Researched for
Recovery

At a glance

Type
Peptide
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
1.75 mg per Peptide Dosing Protocols. All 3 sources

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 1.75 mg, the figure Peptide Dosing Protocols reports for PT-141. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for PT-141 or for anything else, and nothing below has been checked against the study it came from.

1.75 mg
Frequency
not stated
Route
subcutaneous or oral
Reported by
Peptide Protocol Wiki
Standard: 1.75 mg
Frequency
1 dose per 24 hours8 doses per month
Route
Subcutaneous (abdomen or thigh)
Reported by
Peptide Dosing Protocols
What it saysThe standard dose of PT-141 is 1.75 mg subcutaneous at least 45 minutes before sexual activity.
Injection referenced at 0.5-2 mg per dose with onset in 1-4 hours, peak at 6-12 hours, duration 24-72 hours. Nasal spray referenced at 2-4 sprays per nostril, onset 30-60 minutes, duration 6-12 hours. Start low; side effects are dose-dependent (nausea most common).
Frequency
As needed · On-demand, 1-4 hours before desired effect (injection)
Route
subcutaneous or nasal
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • reconstitution math, route considerations, and side effects for this bremelanotide peptide.
Watch first
1:24
0:001:24

The best origin story in the whole series: it started life as a tanning drug, and the side effect became the product.

Not yet audited

We have not published an audit on PT-141. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

PT-141 acts through the central nervous system rather than by changing blood flow, so it works differently from drugs such as sildenafil. Researchers tie its effects on sexual behaviour to melanocortin activity at MC4R in the paraventricular nucleus of the hypothalamus. It also acts at MC1R, which is linked to the darkening of skin, gums and breast tissue on the label, and it slows stomach emptying, which is tied to nausea. Phase 3 evidence exists only for premenopausal women with the approved condition, not for men, postmenopausal women or the nasal route.

In technical termsPT-141 (bremelanotide) is a synthetic cyclic peptide that activates two melanocortin receptors in the brain, MC3R and MC4R, working through the central nervous system rather than by changing blood flow. [Source: Peptide Dosing Protocols]

Reported side effects

Seen in studies: nausea was the most common adverse event in Phase 3, reported by roughly 40 percent of people taking bremelanotide, usually mild to moderate and easing with repeated use. Flushing in the first hour, headache and reactions at the injection site were also reported. A short-lived rise in blood pressure of a few mmHg peaked within hours and returned to baseline. Darkening of skin, gums or breast tissue appears on the label and is described as rare with the approved on-demand pattern.

Not ruled out: nasal-spray versions sold as compounded products have not been evaluated in Phase 3, and the amount delivered per spray varies with the device, technique and nasal congestion. Quality control for any product that is not FDA-approved is a separate risk, and combining PT-141 with other melanocortin agonists such as Melanotan II has no supporting clinical data.

Who should avoid it

People with uncontrolled high blood pressure or known cardiovascular disease: the label contraindicates use because of the short-lived rise in blood pressure after a dose.

People who are pregnant or planning a pregnancy: use is not recommended, and there is no adequate safety data for breastfeeding.

Postmenopausal women and men: the Vyleesi label states they should not use it, and it is not approved to enhance sexual performance.

People with severe kidney or liver disease: clearance may be slowed.

People with conditions that delay stomach emptying: melanocortin activity slows emptying further.

People taking naltrexone: it is listed as a notable interaction, with PT-141 possibly reducing naltrexone exposure.

People using another melanocortin agonist such as Melanotan II: the receptors overlap, effects can compound, and the combination has not been studied.

What gets monitored

Blood pressure, nausea severity, and any darkening of the skin, gums, or breasts; clinician check-in suggested if condition has not improved after 8 weeks. (reported by Peptide Dosing Protocols)

Common questions

What is PT-141?

PT-141 is the research name for bremelanotide, a lab-made ring-shaped peptide. It switches on the melanocortin MC3R and MC4R receptors in the brain.

What is the FDA-approved PT-141 regimen?

Reported amounts and schedules for PT-141 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Is PT-141 approved for men?

No. The FDA approval covers premenopausal women with acquired, generalized hypoactive sexual desire disorder, and the label states that men should not use it. Earlier Phase 2 work in men was not advanced to Phase 3.

Is PT-141 nasal spray FDA-approved?

No. The FDA-approved bremelanotide product is an injection sold as Vyleesi. Nasal versions are compounded products that have not been evaluated in Phase 3 trials.

How long does PT-141 take to work?

Reported amounts and schedules for PT-141 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What are the most common side effects?

Nausea is the most common adverse event, reported in about 40 percent of users in Phase 3 trials. Flushing, headache and injection-site reactions were also reported, mostly mild to moderate and decreasing over time.

Who should avoid PT-141?

The label rules it out for people with uncontrolled high blood pressure or known cardiovascular disease. Postmenopausal women, men, and people who are pregnant or planning a pregnancy also fall outside the approved use.

Can PT-141 be combined with sildenafil or tadalafil?

There is no formal clinical evidence on combining PT-141 with PDE5 inhibitors such as sildenafil or tadalafil.

Sources

  1. 01Mayo Clinic / Merative Micromedex Bremelanotide (subcutaneous route) — Description and Dosing. Mayo Clinic Drugs & Supplements (2026)
  2. 02Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology (2019)
  3. 03Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology (2019)
  4. 04Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health (London) (2016)
  5. 05Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research (2006)
  6. 06Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. Journal of Sexual Medicine (2008)
  7. 07Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences USA (2004)
  8. 08Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women's Health (2022)
  9. 09Pfaus J, Giuliano F, Gelez H. Bremelanotide: An overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine (2007)
  10. 10Loti Labs (Editorial). PT-141 (Bremelanotide): Melanocortin Receptor Agonist Research Guide. Loti Labs Resources (2026)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things